The trial of the OX513A strain of the dengue-carrying Aedes aegypti mosquito, developed by UK biotechnology company Oxitec, was carried out on Grand Cayman island by the Cayman Islands’ Mosquito Research and Control Unit (MRCU) in 2009, followed by a bigger release between May and October this year. Together they represent the first known release of GM mosquitoes anywhere in the world. The male GM mosquitoes mate with normal females to produce larvae that die unless the antibiotic tetracycline is present. In tetracycline’s absence an enzyme accumulates to a toxic level, killing the larvae. The developers hope the strategy could be combined with other mosquito control methods to reduce transmission in dengue-prone areas.
Bio-weaponry mosquito engineering: 1984
TESTING BRUCELLOSIS VIA MOSQUITO VECTOR IN ONTARIO The mosquitoes were then let loose in certain communities in the middle of the night so they could determine how many people would become ill with chronic fatigue syndrome, or fibromyalgia, which was the first disease to show. One of the communities they tested it on was the St. Lawrence Seaway valley all the way from Kingston to Cornwall in 1984. They let out absolutely hundreds of millions of infected mosquitoes. Over 700 people in the next four or five weeks developed myalgic encephalomyelitis, or chronic fatigue syndrome.” Read more…
“TESTING BRUCELLOSES VIA MOSQUITO VECTOR IN PUNTA GORDA
A report from The New England Journal of Medicine, August 22, 1957, p.362
They (mosquitos) were bred in Belleville, Ontario, and taken down and released in Punta Gorda. Within a week, the first five cases ever of chronic fatigue syndrome were reported to the local clinic in Punta Gorda, and it continued until finally 450 people were ill with the disease. Read more…
